India Share Brokers | Equity Trading India | Derivative Trading in India | Share Brokers in India

Markets Navigation

Company Info.

GlaxoSmithKline Pharmaceuticals Ltd.

Income Statement - Consolidated

Market Cap.(`)	35631.17 Cr.	P/BV	20.44	Book Value (`)	102.89
52 Week High/Low ( ` )	2524/1243	FV/ML	10/1	P/E(X)	57.78
Book Closure	30/06/2023	EPS (`)	36.41	Div Yield (%)	1.52

(` in Crs.)

You can view the Consolidated Income Statement for the last 5 years.

Particulars	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19
Months	12	12	12	12	12
Source Of Info (AR = Annual Report, PR = Press Release)	AR	AR	AR	AR	AR
FaceValue	10.00	10.00	10.00	10.00	10.00


INCOME
Revenue From Operations [Net]	3226.38	3264.08	2895.75	3187.35	3089.48
Other Operating Revenues	25.34	13.95	29.86	37.03	38.63
Total Operating Revenues	3251.72	3278.03	2925.60	3224.38	3128.12

Other Income	100.66	75.78	110.58	79.01	102.32
Total Revenue	3352.38	3353.80	3036.18	3303.39	3230.44

EXPENSES
Cost Of Materials Consumed	427.49	611.18	471.78	474.38	686.57
Purchase Of Stock-In Trade	788.43	729.44	823.09	868.92	645.89
Operating And Direct Expenses	73.85	0.00	0.00	0.00	0.00
Changes In Inventories Of FG,WIP And Stock-In Trade	68.96	15.57	-38.02	-35.43	25.57
Employee Benefit Expenses	594.99	610.23	616.16	628.55	537.20
Finance Costs	1.81	2.00	3.53	6.34	0.55
Depreciation And Amortisation Expenses	65.77	68.19	78.60	82.68	48.59
Other Expenses	493.73	549.73	454.45	630.71	632.10
Total Expenses	2515.02	2586.33	2409.60	2656.15	2576.47

Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax	837.37	767.47	626.59	647.25	653.97

Exceptional Items	-0.97	11.58	-172.60	-341.49	28.70
Profit/Loss Before Tax	836.40	779.05	453.99	305.75	682.67

Tax Expenses-Continued Operations
Current Tax	247.13	219.74	158.67	235.31	192.82
Deferred Tax	-18.37	-9.40	8.05	-47.62	44.45
Tax For Earlier Years	0.00	187.94	0.00	24.86	0.00
Total Tax Expenses	228.76	398.28	166.72	212.55	237.28
Profit/Loss After Tax And Before ExtraOrdinary Items	607.64	380.77	287.27	93.20	445.39

Profit/Loss From Continuing Operations	607.64	380.77	287.27	93.20	445.39

Profit/Loss From Discontinuing Operations	4.13	1708.18	96.51	0.00	0.00
Total Tax Expenses Discontinuing Operations	1.08	394.23	25.63	0.00	0.00
Net Profit/Loss From Discontinuing Operations	3.04	1313.95	70.88	0.00	0.00
Profit/Loss For The Period	610.69	1694.72	358.15	93.20	445.39

Minority Interest	6.04	0.00	0.00	0.00	0.00
Consolidated Profit/Loss After MI And Associates	616.72	1694.72	358.15	93.20	445.39

OTHER INFORMATION

EARNINGS PER SHARE
Basic EPS (Rs.)	36.08	99.29	31.35	5.50	26.29
Diluted EPS (Rs.)	36.05	100.04	21.14	5.50	26.29

DIVIDEND AND DIVIDEND PERCENTAGE
Equity Share Dividend	1524.66	508.22	677.62	338.81	296.46
Tax On Dividend	0.00	0.00	0.00	69.64	60.94

GlaxoSmithKline Pharmaceuticals Ltd.

Balance Sheet - Consolidated

Market Cap.(`)	35631.17 Cr.	P/BV	20.44	Book Value (`)	102.89
52 Week High/Low ( ` )	2524/1243	FV/ML	10/1	P/E(X)	57.78
Book Closure	30/06/2023	EPS (`)	36.41	Div Yield (%)	1.52

(` in Crs.)

You can view the Consolidated Balance Sheet for the last 5 years.

Particulars	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19
Months	12	12	12	12	12
Source Of Info (AR = Annual Report, PR = Press Release)	AR	AR	AR	AR	AR
FaceValue	10.00	10.00	10.00	10.00	10.00
No. of Equity Shares (in Lacs)	1694.06	1694.06	1694.06	1694.06	1694.06

EQUITIES AND LIABILITIES
SHAREHOLDER'S FUNDS
Equity Share Capital	169.41	169.41	169.41	169.41	169.41
Total Share Capital	169.41	169.41	169.41	169.41	169.41

Reserves and Surplus	1573.54	2493.55	1308.85	1651.20	1970.42
Total Reserves and Surplus	1573.54	2493.55	1308.85	1651.20	1970.42
Employees Stock Options	-1.68	0.00	0.00	0.00	0.00
Total Shareholders Funds	1741.27	2662.96	1478.26	1820.60	2139.83

NON-CURRENT LIABILITIES
Long Term Borrowings	0.00	0.00	0.00	0.02	0.18
Other Long Term Liabilities	4.14	9.68	22.31	28.91	2.21
Long Term Provisions	254.80	262.21	259.50	261.74	314.78
Total Non-Current Liabilities	258.94	271.89	281.81	290.68	317.16

CURRENT LIABILITIES
Short Term Borrowings	0.00	0.00	0.02	0.00	0.00
Trade Payables	427.79	570.55	466.13	357.06	405.81
Other Current Liabilities	480.79	799.90	613.80	384.22	956.14
Short Term Provisions	417.79	327.98	274.62	280.67	92.36
Total Current Liabilities	1326.37	1698.43	1354.58	1021.95	1454.32

Total Capital And Liabilities	3326.58	4633.28	3114.65	3133.23	3911.31

ASSETS
NON-CURRENT ASSETS
Tangible Assets	295.87	296.15	343.55	708.46	366.09
Intangible Assets	34.09	34.50	43.36	49.63	65.54
Capital Work-In-Progress	20.31	30.50	13.21	120.12	1002.64
Fixed Assets	350.27	361.15	400.12	878.21	1434.27
Non-Current Investments	0.00	0.00	0.00	0.00	0.06
Deferred Tax Assets [Net]	133.55	113.15	103.13	110.49	62.22
Long Term Loans And Advances	70.00	190.00	0.00	8.22	11.84
Other Non-Current Assets	278.50	260.95	408.76	361.45	393.46
Total Non-Current Assets	832.32	925.25	912.01	1358.35	1901.85


CURRENT ASSETS
Current Investments	518.29	365.59	0.00	0.00	0.00
Inventories	459.97	534.70	546.70	483.03	486.49
Trade Receivables	192.38	205.24	215.60	99.80	120.49
Cash And Cash Equivalents	1155.93	2484.51	1157.96	1083.20	1171.35
OtherCurrentAssets	167.70	118.00	282.37	108.84	231.14
Total Current Assets	2494.26	3708.03	2202.64	1774.88	2009.46

Total Assets	3326.58	4633.28	3114.65	3133.23	3911.31

OTHER INFORMATION

CONTINGENT LIABILITIES, COMMITMENTS
Contingent Liabilities	361.80	368.97	498.50	488.30	594.73

BONUS DETAILS
Bonus Equity Share Capital	125.39	125.39	125.39	125.39	125.39

NON-CURRENT INVESTMENTS
Non-Current Investments Unquoted Book Value	0.00	0.00	0.00	0.00	0.06

Attention Investors : “Prevent unauthorized transactions in your account ? Update your Mobile Numbers/Email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your Mobile/Email at the end of the day. Issued in the interest of Investors” ***** No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorize your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. | | ***** KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary. | "Revised guidelines on margin collection ==> 1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. | 2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. | 3. Pay 20% upfront margin of the transaction value to trade in cash market segment. | 4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. | 5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. .......... Issued in the interest of Investors" | ***** MEMBERS : SEBI Regn. No: NSE, BSE: INZ000176636 ; MCX : INZ000057535; SEBI Research Analyst Regn No: INH200000337; AMFI Regn No. 77624; Depository Participant : CDSL : IN-DP-CDSL-379-2006 DP ID : 12047600 | For any Grievance mail to : grievance@sharewealthindia.com | For any DP Grievance mail to : dpgrievance@sharewealthindia.com. | Grievance with SEBI : https://scores.gov.in/scores/Welcome.html

Share Wealth

GlaxoSmithKline Pharmaceuticals Ltd.

Income Statement - Consolidated

GlaxoSmithKline Pharmaceuticals Ltd.

Balance Sheet - Consolidated